Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 132906-53-7 | MDL No. : | MFCD02053395 |
Formula : | C12H10BrNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FEGZZTGHQHATDN-UHFFFAOYSA-N |
M.W : | 264.12 | Pubchem ID : | 878731 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.25 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 63.85 |
TPSA : | 32.86 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | Yes |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.66 cm/s |
Log Po/w (iLOGP) : | 2.29 |
Log Po/w (XLOGP3) : | 3.17 |
Log Po/w (WLOGP) : | 3.45 |
Log Po/w (MLOGP) : | 2.43 |
Log Po/w (SILICOS-IT) : | 4.25 |
Consensus Log Po/w : | 3.12 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.92 |
Solubility : | 0.0319 mg/ml ; 0.000121 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.53 |
Solubility : | 0.0778 mg/ml ; 0.000295 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -5.13 |
Solubility : | 0.00194 mg/ml ; 0.00000733 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 2.07 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
67% | at 20℃; for 0.166667 h; | General procedure: To a solution of 2-(substituted phenylamino)cyclohex-2-enone 1 (0.6 mmol) in Ac2O (10 mL) was added a solution of PIFA(0.66 mmol) in Ac2O (2 mL) in a dropwise manner. The reactionmixture was stirred at room temperature for 10 min, monitored byTLC. Then the solution was poured into saturated NaHCO3 solution(50 mL) and NaHCO3 (solid) was added portionwise while themixture was stirred vigorously until no more CO2 emerged. Themixture was extracted with EA (20 mL3), and the combined organiclayerwaswashed by brine (20 mL), dried with NaSO4, filtered,and concentrated under vacuum. Purification of the crude residueby column chromatography using PE and EA as eluent gave compounds 2a-l. |
[ 944086-09-3 ]
1-(7-Bromo-1H-indol-3-yl)ethanone
Similarity: 0.83
[ 76228-06-3 ]
6-Bromo-2,3-dihydroquinolin-4(1H)-one
Similarity: 0.78
[ 21865-50-9 ]
6-Bromo-2,3,4,9-tetrahydro-1H-carbazole
Similarity: 0.77
[ 877-03-2 ]
5-Bromo-1H-indole-3-carbaldehyde
Similarity: 0.74
[ 944086-09-3 ]
1-(7-Bromo-1H-indol-3-yl)ethanone
Similarity: 0.83
[ 3449-48-7 ]
6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one
Similarity: 0.79
[ 76228-06-3 ]
6-Bromo-2,3-dihydroquinolin-4(1H)-one
Similarity: 0.78
[ 3449-48-7 ]
6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one
Similarity: 0.79
[ 21865-50-9 ]
6-Bromo-2,3,4,9-tetrahydro-1H-carbazole
Similarity: 0.77
[ 15128-52-6 ]
2,3-Dihydro-1H-carbazol-4(9H)-one
Similarity: 0.73
[ 497261-38-8 ]
8-Bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
Similarity: 0.71
[ 205584-61-8 ]
8-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine
Similarity: 0.70